<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754312</url>
  </required_header>
  <id_info>
    <org_study_id>SNDX-275-0302</org_study_id>
    <nct_id>NCT00754312</nct_id>
  </id_info>
  <brief_title>A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer</brief_title>
  <official_title>A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syndax Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syndax Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate changes in the expression of targeted
      biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study has been transfered from a sponsored trial to an investigator initiated trial.
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes in gene and/or protein expression of exploratory biomarkers in invasive breast cancer tissue before and after SNDX-275 administration, as tissue sample permits.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability of SNDX-275 as measured by adverse events and changes in laboratory safety parameters</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER negative and/or PR negative histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>triple negative histology (for ER, PR, HER-2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNDX-275</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram

          -  Must be able to receive two doses of study medication 7 days apart prior to surgery

          -  Has histologically confirmed invasive breast cancer with ER positive, ER and/or PR
             negative histology or triple negative (for ER, PR, HER-2) histology

          -  Has an ECOG performance status ≤ 2

          -  Has no clinically significant laboratory or cardiac abnormalities

          -  Has a negative serum pregnancy test at Screening as is either post menopausal, sterile
             or willing to use an approved method of contraception.

          -  Is able to swallow and retain oral medication

        Exclusion criteria:

          -  Has a concomitant medical condition that precludes adequate study treatment compliance
             or assessment, such as: a. Bleeding disorders that would increase risks of additional
             core biopsy for biomarkers b. Morbid obesity

          -  Is currently receiving treatment with a medication on the prohibited medication list

          -  Has allergy to benzamides or inactive components of study drug

          -  Is participating in another clinical trial or has received another investigational
             agent within 30 days prior to informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monet Bowling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Baildam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Christie Hospital, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monet Bowling, MD</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <last_update_submitted>February 2, 2010</last_update_submitted>
  <last_update_submitted_qc>February 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Judy Billingsley, Clinical Program Manager</name_title>
    <organization>Syndax Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

